Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Taiwan Liposome Company Ltd (4152) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7996
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taiwan Liposome Company Ltd (TLC) is a clinical-stage pharmaceutical company that develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and oncology. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan.

Taiwan Liposome Company Ltd (4152) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Licensing Agreements 15
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Equity Offering 17
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Acquisition 22
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd – Key Competitors 23
Taiwan Liposome Company Ltd – Key Employees 24
Taiwan Liposome Company Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Product News 26
10/16/2017: TLC Showcases Pain Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 26
10/11/2017: TLC to Present Update on Anesthetic Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 27
01/09/2017: Results of Phase 1/2 Clinical Trial of TLC599 in the Treatment of Osteoarthritis of the Knee 28
Product Approvals 29
Apr 03, 2018: TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug 29
Clinical Trials 30
Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 30
Jul 11, 2017: TLC Announces Issuance of Patent for Dexamethasone Sodium Phosphate 31
Jan 03, 2017: TLC to Proceed with TLC599 Phase 2 Trial in Taiwan 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd, Key Competitors 23
Taiwan Liposome Company Ltd, Key Employees 24
Taiwan Liposome Company Ltd, Other Locations 25
Taiwan Liposome Company Ltd, Subsidiaries 25

List of Figures
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PICC Property and Casualty Co Ltd:企業の戦略・SWOT・財務情報
    PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report Summary PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Inivata Ltd:企業の製品パイプライン分析2018
    Summary Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in …
  • Shinva Medical Instrument Co Ltd (600587):医療機器:M&Aディール及び事業提携情報
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s product portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instrum …
  • Companhia Energetica do Rio Grande do Norte SA (CSRN3):企業の財務・戦略的SWOT分析
    Summary Companhia Energetica do Rio Grande do Norte SA (COSERN), a subsidiary of Neoenergia SA, is an electric utility that distributes electricity. The utility offers services such as online bill payment, energy conservation, electrical safety, energy efficiency, energy audits, connect and disconne …
  • Orpea SA (ORP):企業の財務・戦略的SWOT分析
    Summary Orpea SA (Orpea) is a healthcare consulting company that offers clinical care services. The company provides services such as suite care clinic services, retirement homes, and mental hospital services, among others. Its mental hospital services include treatment of mood disorders, overuse sy …
  • Automatic Data Processing Inc (ADP):企業の財務・戦略的SWOT分析
    Automatic Data Processing Inc (ADP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Kemwell Biopharma Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd, a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentr …
  • Suzano Papel e Celulose SA (SUZB5):企業の財務・戦略的SWOT分析
    Suzano Papel e Celulose SA (SUZB5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Toho Holdings Co Ltd (8129):企業の財務・戦略的SWOT分析
    Toho Holdings Co Ltd (8129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bangkok Insurance Pcl
    Bangkok Insurance Pcl - Strategy, SWOT and Corporate Finance Report Summary Bangkok Insurance Pcl - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Attunity Ltd (ATTU):企業の財務・戦略的SWOT分析
    Summary Attunity Ltd (Attunity) is a technology company that provides data management software, cloud database replication solutions, and google cloud database tools. The company provides data management software solutions that enable access, sharing, management, and distribution of data. It offers …
  • Schroders Plc:企業の戦略・SWOT・財務情報
    Schroders Plc - Strategy, SWOT and Corporate Finance Report Summary Schroders Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Biman Bangladesh Airlines Ltd.:企業の戦略・SWOT・財務情報
    Biman Bangladesh Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary Biman Bangladesh Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hobby Lobby Stores Inc:戦略・SWOT・企業財務分析
    Hobby Lobby Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Hobby Lobby Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Showa Denko Materials Co Ltd:企業の戦略的SWOT分析
    Showa Denko Materials Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Fujitsu Australia Ltd:企業の戦略的SWOT分析
    Fujitsu Australia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Allegiance Capital Corporation:企業の戦略・SWOT・財務分析
    Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • 3W Power S.A. (3W9K):企業の財務・戦略的SWOT分析
    3W Power S.A. (3W9K) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Brazil Fast Food Corp.:企業の戦略・SWOT・財務分析
    Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report Summary Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Knight-Swift Transportation Holdings Inc. (KNX):企業の財務・戦略的SWOT分析
    Knight-Swift Transportation Holdings Inc. (KNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆